Pharmaceutical composition for treating steatohepatitis and preparation method of pharmaceutical composition

A steatohepatitis and composition technology, which is applied in the field of pharmaceutical preparations, can solve the problems of elimination of candidate drugs for solubilization requirements, and achieve the effects of avoiding drug degradation reactions, improving dissolution rate, and avoiding dust pollution
CN113274368AActive Publication Date: 2021-08-20GANNEX PHARM CO LTD
6 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
GANNEX PHARM CO LTD
Publication Date
2021-08-20

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a pharmaceutical composition for treating steatohepatitis and a preparation method of the pharmaceutical composition. The pharmaceutical composition comprises the following components in parts by weight: (a) 1 part of a compound shown in a formula (I); (b) 16-600 parts of a meltable dispersion carrier, wherein the meltable dispersion carrier comprises poloxamer and polyethylene glycol, and the weight ratio of the poloxamer to the polyethylene glycol is 1:(0.5-27); and (c) 0.2-100 parts of non-volatile weak acid. The pharmaceutical composition is beneficial to greatly improving the in-vitro dissolution rate of the compound shown in the formula (I), and meanwhile, the stability of the compound shown in the formula (I) can be ensured due to mild preparation conditions.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a pharmaceutical composition for treating steatohepatitis and a preparation method thereof. Background technique

[0002] Compound shown in formula (I) (molecular formula is C 28 h 32 ClO 5 P, molecular weight 514.98, CAS registration number 852948-13-1) is a novel oral thyroid hormone β receptor agonist (THR-beta agonist), which regulates downstream CYP7A and SREBP- The expression of genes such as 1c can effectively promote the decomposition of fatty acids and stimulate the biogenesis of mitochondria, reduce the level of low-density lipoprotein and triglyceride, thereby reducing lipotoxicity and improving liver function, reducing liver fat. Drug candidates for alcoholic steatohepatitis (NASH).

[0003]

[0004] The compound represented by the formula (I) is a poorly soluble drug with strong fat solubility. As a result of measuring its equilibrium so...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More